Another Healthcare Stock Stealing The Show

Sponsored:

Tuesday, January 9, 2024

A Washington-based healthcare company found tremendous success on Tuesday after the company announced it has signed multiple strategic agreements with Lantheus Holdings, including a $33 million share purchase agreement. According to the release, Lantheus has agreed to buy up to 19.9% of the company’s outstanding stock.

Shares of Perspective Therapeutics (NYSE American:CATX) rallied strongly on the news, with shares of this small cap closing up at $0.644/share (+9.15%) on the day. This move is a strong continuation of the success this stock has found over the last month. 

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.

Sponsored: